The company also posted a net loss of $73,000, or $0.00 per share, compared to net earnings of $143,000, or $0.01 per share, for the same quarter in 2011.
RBC Life Sciences president and CEO Clinton H. Howard said in the first quarter of this year, the company’s Associate network channel continued its growth trend with an increase of 4%.
"Sales of our new dietary supplement product, Stem-Kine™, continued to be a positive factor in this channel along with improving sales results in the Taiwan market, which we opened last year," H. Howard added.
"The net loss for the quarter was primarily attributable to a $140,000 non-recurring charge that resulted from the disposal of inventory that did not meet our quality standards."
Stem-Kine is a dietary supplement that nutritionally enables bone marrow and other stem-cell-producing tissues to produce an increased level of circulating stem cells.